Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Sarsia is an early-stage venture capital firm founded in 2003 and based in Norway. The firm manages a fund size of 1 billion EUR and focuses on investing in technologies that contribute to a greener and healthier future. Sarsia has a portfolio of 22 companies, emphasizing its commitment to sectors like biotech and clean energy.
Sarsia invests in pre-seed, seed, and Series A stages, primarily in Life Sciences and Technology, Energy, and Sustainability sectors. The firm targets unmet medical needs in Life Sciences and seeks to accelerate the green transition through innovative technologies in energy and sustainability. Check sizes typically range from early-stage investments to significant funding for promising startups.
Notable companies in Sarsia's portfolio include Vestland Pharma AS, which focuses on using nature to combat salmon lice; Flow Computing, known for energy-efficient CPU performance; and Calluna Pharma, a clinical-stage company pioneering new medical approaches. Other portfolio companies include Cetasol, Chargitect, SonoClear, and ScreenCancer AS.
Submit your pitch through their form at sarsia.com.
Yes, Sarsia often leads investment rounds, particularly in early-stage companies that align with their focus on life sciences and sustainability.
Sarsia is open to follow-on investments, especially for companies that demonstrate significant progress and align with their investment thesis.
Sarsia manages a fund size of 1 billion EUR, allowing for substantial investments in promising startups.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.